Monkeypox: New Potential Pandemic Approaching, Disregard Compliance Calls
In the ongoing global response to the monkeypox outbreak, BioNTech, the German biotechnology company renowned for its mRNA COVID-19 vaccine technology, is taking significant steps towards developing vaccines against the disease.
BioNTech is constructing its first commercial African vaccine factory in Rwanda, with a focus on mRNA vaccines against Mpox. The European Commission President Ursula von der Leyen and German Foreign Minister Annalena Baerbock attended the factory's opening, which has raised questions about potential conflicts of interest. Germany is providing nearly 36 million euros of funding to support vaccine production in Rwanda.
The company's expansion efforts also include a strategic partnership with the Coalition for Epidemic Preparedness Innovations (CEPI), entered into in late 2023. CEPI, an alliance of the WHO, the EU Commission, governments, pharmaceutical companies, private donors, and foundations, was founded in Davos in 2016.
Notably, the Wellcome Trust, the Gates Foundation, and the UN are significant investors in CEPI's portfolio.
Meanwhile, BioNTech's African vaccine factory is not the only initiative aimed at combating monkeypox. In May 2024, BioNTech and CEPI announced they were expanding their portfolio for mRNA vaccines, including vaccines against Mpox.
However, concerns about potential conflicts of interest and the role of key players in the monkeypox vaccine development have been raised. Christine Anderson, a Member of the European Parliament, has written two open letters expressing her concerns about monkeypox and potential conflicts of interest.
The Austrian Red Cross (Tyrol section) is also actively involved in the monkeypox response, hiring for vaccination center roles. Applicants are expected to be "assertive" and tasks include managing patient flows, preparing vaccination certificates, and carrying out mobile vaccinations.
It is important to note that there is no confirmed connection between Christine Anderson, BioNTech, CEPI, and monkeypox vaccines as discussed in her open letters. The search results do not mention Christine Anderson discussing BioNTech, CEPI, or monkeypox vaccines, nor do they reference any connection among these entities in her communications.
In the face of the ongoing monkeypox outbreak, it is crucial that the public remains informed and vigilant. The only approved monkeypox vaccine in both the EU and the USA is "Imvanex" from "Bavarian Nordic."
As the situation evolves, it is essential to follow the guidance of health authorities and stay updated on the latest developments in monkeypox vaccine research and distribution.
- The partnership between BioNTech and CEPI, an alliance focused on epidemic preparedness, has led to the expansion of their mRNA vaccine portfolio, including potential vaccines against Mpox.
- Despite concerns about potential conflicts of interest, BioNTech, with funding from Germany, is constructing its first commercial African vaccine factory in Rwanda, aiming to produce mRNA vaccines against Mpox.
- In the health-and-wellness field, it's crucial to emphasize the importance of mental health during times of global health crises, such as the ongoing monkeypox outbreak, and remain informed about the truth regarding key players and vaccine developments.
